Success Stories: A Senior Scientist in the Cancer Biology Field from Vietnam Obtains NIW Approval in Less Than 3 Months, Thanks to Our Excellent Case Preparation
Client’s Testimonial:
“Thank you so much for your help and for your excellent work.”
On April 16th, 2022, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Scientist in the Field of Cancer Biology (Approval Notice).
General Field: Cancer Biology
Position at the Time of Case Filing: Senior Scientist
Country of Origin: Vietnam
State of Residence at the Time of Filing: Maryland
Approval Notice Date: April 16th, 2022
Processing Time: 2 months, 16 days
Case Summary:
“[The client] is a cancer biologist who has worked to discover the genetic and epigenetic roots of cancers, including an aggressive form of pediatric cancer known as malignant rhabdoid tumors. In conducting this research, she is contributing to the well-being of cancer patients now and in the future who will have access to better-targeted and less toxic therapies.”
This is one of several such statements issued for a client from Vietnam who had come to us seeking help with her NIW (National Interest Waiver) petition. As one can note, the above statement is clear in stating the significance of her work for the target groups. This meant that her work was of value to the country and the world at large.
Our team found that as an expert in the field of cancer biology, her proposed endeavor is to continue utilizing her expertise in advanced molecular, chromosomal, and DNA tools to investigate the mechanisms of chromosomal rearrangement that drive cancer in order to identify novel therapies. This meant that her proposed endeavor is of great importance because it provides the basis for more effective cancer therapeutics that are based on an improved understanding of the pathophysiology of the disease.
So, our client’s research on malignant rhabdoid tumors, which is a particularly aggressive form of childhood cancer, provides the key discoveries that are necessary to design therapeutics based on a more accurate model of the underlying mechanisms of the disease. The client has expanded the capabilities of research in this area and opened new avenues for strategic approaches to the disease that more fully address the longstanding questions that have stymied therapeutics research and development efforts. The client has thus not only provided the foundation for developing novel castrate-resistant prostate cancer lines that enable the study of the molecular mechanisms of castration resistance but also established an innovative analytical framework for genomic studies using long-range sequencing. Her work has also drawn funding from institutions such as the National Institute of Health (NIH), the National Cancer Institute (NCI), the Prostate Cancer Foundation, and the Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP).
On the other hand, in her 7 years pursuing this proposed work, her research has resulted in four peer-reviewed journal articles and one first-authored publication. And these publications have been cited a total of 34 times according to Google Scholar. We also thought it useful to give detailed descriptions of 4 of her key projects that have been included as evidence of her contributions to and expertise in the field of cancer biology.
The evidence thus shows that her research on the chromosomal rearrangement mechanisms underlying cancer holds significant value for the research and development of therapeutics for childhood cancers and prostate cancer, which impact millions of Americans. We are thus glad to have worked with her and won her the NIW approval. We also wish her the best in life.